A COVID-19 vaccine candidate under development by pharma giant Pfizer and biotech firm BioNTech showed promise in interim results released Wednesday. The vaccine candidate, BNT162b1, was able to induce the formation of antibodies that neutralized SARS-CoV-2, the virus that causes COVID-19, in all participants who received doses between 10ug to 30ug, according to a report […] Continue reading ->
A six-vial five-day course of remdesivir – a promising COVID-19 treatment – will be priced at US $2340, or $390 per vial for developed countries, Gilead Sciences Chief Executive Officer Daniel O’Day wrote in an open letter on Monday. “Earlier hospital discharge [thanks to treatment by remdesivir] would result in hospital savings of approximately $12,000 […] Continue reading ->
A standardized set of more than 80 compounds with known or predicted activity against SARS-CoV-2, the virus that causes COVID-19, has been compiled by the Medicines for Malaria Venture in an effort to catalyze the discovery of drugs for the disease. The announcement comes amidst rapid shifts in the research around potential COVID-19 treatments. Just […] Continue reading ->
A rising star in the COVID-19 treatment arena, dexamethasone – a powerful corticosteroid – has stirred excitement among World Health Organization experts and researchers around the world, following the publication of promising early results from the United Kingdom’s Recovery trial.  In COVID-19 patients only receiving supplemental oxygen, the trial found that dexamethasone reduced mortality by […] Continue reading ->
A major clinical trial ongoing in the United Kingdom has fingered dexamethasone, a common anti-inflammatory drug used to treat arthritis and asthma, as the “first” treatment to actually reduce mortality among COVID-19 patients – by as much as one-third.  The preliminary findings were announced by the trial’s principal investigators, Martin Landray and Peter Horby, both […] Continue reading ->